Biopharmaceutical Firm Cingulate Prices US$25 Million IPO
Clinical-stage biopharmaceutical company Cingulate Inc. (Nasdaq: CING) began trading on the Nasdaq Capital Market today. The firm’s initial public offering
Read moreClinical-stage biopharmaceutical company Cingulate Inc. (Nasdaq: CING) began trading on the Nasdaq Capital Market today. The firm’s initial public offering
Read more